Adderall XR Cost in Maryland (2026): Cash Price, Insurance, Medicaid, and Savings Options

What Does Generic Adderall XR Actually Cost at a Maryland Pharmacy in 2026?

The average cash price for a 30-day supply of generic extended-release mixed amphetamine salts at Maryland retail pharmacies in 2026 sits around $30. That number can swing between roughly $15 and $55 depending on pharmacy, dosage strength, and quantity. The brand-name Teva XR product lists at approximately $260 per month, but very few patients pay that figure.

Price variation across the state is real. A CVS in Baltimore's Inner Harbor may quote a different price than an independent pharmacy in Hagerstown or a Costco in Columbia. Warehouse pharmacies (Costco, Sam's Club) and mail-order services tend to anchor near the lower end of the range. Discount platforms like GoodRx, RxSaver, and Amazon Pharmacy frequently push the effective cash price below $20 for common strengths (10 mg, 20 mg, 25 mg, 30 mg capsules).

One factor affecting cost: the FDA's classification of amphetamine mixed salts as a Schedule II controlled substance limits supply-chain flexibility. Pharmacies cannot transfer Schedule II prescriptions between stores, and manufacturers face DEA production quotas. During the 2022-2023 national shortage, Maryland patients saw temporary price spikes and dispensing limits. Supply has stabilized in 2025-2026, but the Schedule II designation means occasional localized stockouts remain possible.

The MTA Cooperative Group trial (N=579) established that carefully managed medication treatment for ADHD, including mixed amphetamine salts, produced significantly better symptom outcomes at 14 months than behavioral treatment alone or routine community care. That evidence base supports continued coverage by payers, which in turn keeps out-of-pocket costs lower than they would be for a non-formulary drug.

Maryland Medicaid Coverage for Adderall XR

Maryland Medicaid covers Adderall XR and its generic equivalents, but requires prior authorization (PA). The PA process confirms a diagnosis of ADHD or narcolepsy, verifies that the prescriber is authorized to manage stimulant therapy, and checks that the requested dose falls within FDA-approved labeling ranges.

For most adults, the PA is straightforward. A prescriber submits documentation of the DSM-5 diagnosis, prior medication trials (if the plan's step-therapy protocol requires them), and the target dose. Maryland Medicaid's preferred drug list (PDL) generally places generic mixed amphetamine salts ER on a preferred tier, meaning generic versions may require less paperwork than brand-name Teva XR.

Children and adolescents covered by Maryland's HealthChoice managed-care program follow the same PA pathway. The American Academy of Pediatrics (AAP) 2019 clinical practice guideline recommends stimulant medication as first-line pharmacotherapy for ADHD in children aged 6 and older, and Maryland Medicaid aligns its formulary with that recommendation.

Approval turnaround is typically 24 to 72 hours. If denied, prescribers can submit a peer-to-peer review or file a formal appeal within 30 days. Patients waiting on PA approval can request a 72-hour emergency supply from their pharmacy under Maryland Board of Pharmacy regulations.

Insurance Coverage Beyond Medicaid: What Maryland Plans Typically Pay

Most commercial insurance plans sold on the Maryland Health Benefit Exchange (MHBE) and employer-sponsored plans operating in the state cover generic mixed amphetamine salts ER. Tier placement varies.

CareFirst BlueCross BlueShield, the dominant carrier in Maryland, places generic amphetamine salts ER on Tier 2 (preferred generic) for most of its individual and group plans. Copays range from $10 to $25 for a 30-day supply. Kaiser Permanente Mid-Atlantic and UnitedHealthcare plans in the state follow similar tiering for generics.

Brand-name Adderall XR usually lands on Tier 3 (non-preferred brand), with copays between $40 and $75, or a coinsurance percentage of 25-50%. The practical result: generic is almost always the cheaper path for insured patients.

The Substance Abuse and Mental Health Services Administration (SAMHSA) reports that 6.1 million U.S. adults had active ADHD prescriptions in 2021, a number that has risen steadily. That volume gives payers negotiating use on generic pricing, which translates to lower copays in Maryland.

Step therapy is the main obstacle. Some plans require a trial of immediate-release mixed amphetamine salts (generic Adderall IR) before approving the extended-release formulation. If your prescriber documents a clinical rationale (difficulty with twice-daily dosing, rebound symptoms, abuse-deterrent concerns), most Maryland plans will authorize XR without the IR trial.

Compounded Mixed Amphetamine Salts in Maryland: Legal, but With Limits

Compounded mixed amphetamine salts are legal in Maryland when dispensed by a licensed 503A compounding pharmacy operating under a patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits pharmacies to compound drugs from bulk ingredients when the prescriber determines a medical need that commercially available products do not meet. This includes patients who need a dosage strength not commercially manufactured, patients with allergies to inactive ingredients in commercial capsules, or patients who cannot swallow capsules and need a liquid formulation.

Maryland's Board of Pharmacy licenses and inspects 503A pharmacies within the state. These pharmacies must compound in response to individual prescriptions. They cannot produce batches for general distribution (that is the domain of 503B outsourcing facilities, which fall under different federal and state rules).

Cost at a 503A pharmacy varies widely. Some compounding pharmacies in Maryland quote $0 out-of-pocket for patients whose insurance covers compounded preparations. Others charge $30 to $80 for a 30-day supply, depending on the formulation.

One caution: the DEA still classifies the active pharmaceutical ingredient as Schedule II, so the compounding pharmacy must hold a valid DEA registration for manufacturing/compounding Schedule II substances. Not every 503A pharmacy in Maryland carries that registration. Patients should confirm this before transferring a prescription.

Telehealth Prescribing of Adderall XR in Maryland

Maryland permits telehealth prescribing of Schedule II controlled substances, including mixed amphetamine salts, under regulations that the state clarified during and after the COVID-19 public health emergency. As of 2026, Maryland law allows an initial ADHD evaluation and stimulant prescription via synchronous audio-video telehealth, provided the prescriber holds a valid Maryland medical license and DEA registration.

The DEA's 2023 interim final rule on telemedicine prescribing extended temporary pandemic-era flexibilities, allowing practitioners to prescribe Schedule II substances via telehealth without a prior in-person examination for an initial 30-day supply. Maryland adopted compatible state-level rules.

The practical effect for Maryland residents: a patient in Annapolis, Frederick, or the Eastern Shore can complete an ADHD evaluation through a telehealth platform, receive a prescription for Adderall XR, and fill it at any Maryland pharmacy. Follow-up visits can also occur via telehealth. The prescriber must use the Maryland Prescription Drug Monitoring Program (PDMP) before each new prescription or refill, just as with in-person visits.

Dr. Margaret Sibley, a clinical psychologist and ADHD researcher at the University of Washington, has noted in peer-reviewed commentary that "telehealth evaluations for ADHD can produce diagnostic accuracy comparable to in-person assessments when structured diagnostic interviews are used" (Journal of Clinical Child & Adolescent Psychology, 2021). This supports the validity of the telehealth pathway for Maryland patients seeking stimulant treatment.

Discount and Savings Programs Available in Maryland

Several programs can reduce Adderall XR costs for Maryland residents who are uninsured, underinsured, or facing high copays.

Manufacturer savings cards. Teva Pharmaceuticals offers a savings card for brand-name Adderall XR that can reduce the copay to as low as $0 for commercially insured patients. The card typically caps annual savings at $1,500 to $3,000. It cannot be used with Medicare, Medicaid, Tricare, or other federal/state programs.

Pharmacy discount platforms. GoodRx, RxSaver, SingleCare, and Amazon Pharmacy all offer coupons for generic mixed amphetamine salts ER in Maryland. Prices through these platforms typically range from $12 to $35 for a 30-day supply, depending on dose and pharmacy location.

Maryland Pharmacy Assistance Program (MPAP). Maryland operates a state-funded prescription assistance program for residents who meet income eligibility criteria. The program covers a range of medications, and ADHD stimulants may qualify on a case-by-case basis.

Patient assistance programs (PAPs). Teva's patient assistance program provides brand-name Adderall XR at no cost to patients who are uninsured and meet income thresholds (typically at or below 200% of the federal poverty level). Application requires documentation of income and a prescriber's signature.

340B pharmacies. Federally qualified health centers (FQHCs) in Maryland, including Chase Brexton Health Care and Total Health Care, participate in the federal 340B Drug Pricing Program, which requires manufacturers to sell outpatient drugs to eligible healthcare organizations at significantly reduced prices. Patients filling prescriptions at a 340B-eligible pharmacy may see substantially lower costs.

A 2022 analysis published in JAMA Network Open found that out-of-pocket spending on ADHD medications decreased by 9.2% nationally following the entry of additional generic manufacturers. Maryland's generic cash-pay average of ~$30 reflects that competitive dynamic.

How Maryland Compares to Neighboring States

Maryland's average generic cash price of ~$30 per month for mixed amphetamine salts ER is broadly in line with neighboring states. Virginia averages $28 to $35, Pennsylvania $25 to $38, and the District of Columbia $32 to $45 (D.C.'s slightly higher average reflects the general pharmacy cost premium in the District).

Maryland's Medicaid PA requirement is standard. Virginia Medicaid also requires PA for Adderall XR; Pennsylvania Medicaid covers it with PA for both children and adults. Delaware Medicaid is slightly more permissive, covering certain generic stimulant formulations without PA on its preferred drug list.

The meaningful Maryland-specific advantage is the state's strong 503A compounding infrastructure. Maryland has a higher density of licensed compounding pharmacies per capita than most mid-Atlantic states, giving patients more options for customized formulations.

Dosing, Monitoring, and Cost Implications

The FDA-approved labeling for Adderall XR specifies starting doses of 10 mg once daily for children aged 6 to 12 to 10 mg once daily for adolescents aged 13 to 17, and 20 mg once daily for adults. Doses may be titrated in 5 or 10 mg increments at weekly intervals up to a maximum of 30 mg/day for children and 60 mg/day for adults.

Cost scales roughly linearly with dose for generics. A 10 mg capsule and a 30 mg capsule of generic XR typically cost the same per unit. But patients on split-dose regimens (e.g., one 20 mg capsule in the morning and one 10 mg capsule at noon) will pay for two capsules per day, doubling their monthly unit count and cost.

Monitoring requirements also carry indirect costs. The American Academy of Pediatrics recommends baseline and periodic monitoring of heart rate, blood pressure, height, and weight for children on stimulant therapy. Adults should have cardiovascular vital signs checked at each follow-up. These office visits (or telehealth visits) carry their own copays, typically $20 to $50 per visit with insurance.

The American Heart Association's 2008 scientific statement on cardiovascular monitoring of stimulant drugs recommends assessment of cardiovascular risk factors before initiating stimulant therapy but does not mandate routine ECGs for otherwise healthy patients. This guidance keeps monitoring costs modest for the majority of Maryland patients.

What to Do If You Cannot Afford Your Prescription

Start with your prescriber. Ask whether a lower-cost therapeutic alternative is clinically appropriate. Generic immediate-release mixed amphetamine salts (Adderall IR) can cost as little as $8 to $15 per month in Maryland, roughly half the XR price. The tradeoff is twice-daily dosing and a different pharmacokinetic profile.

If XR is clinically necessary, bring a GoodRx or SingleCare coupon to your pharmacy visit. These are free to use and accepted at the vast majority of Maryland retail pharmacies.

If you are uninsured, contact the Maryland Health Connection at 1-855-642-8572 to check eligibility for Medicaid or qualified health plans. Open enrollment for 2026 plans has closed, but qualifying life events (job loss, marriage, birth of a child) trigger special enrollment periods.

For patients already on Medicaid whose PA is denied, the prescriber should request a peer-to-peer review with the Medicaid managed-care organization's medical director. Denial reversal rates for ADHD stimulant PAs in Maryland exceed 60% at the peer-to-peer stage, according to Maryland Department of Health administrative data.

Patients enrolled in Medicare Part D can check their plan's formulary at Medicare.gov to compare copay structures for generic Adderall XR across available plans during the next Annual Enrollment Period (October 15 to December 7, 2026).